Gilead Sciences, Inc. stands a strong chance of winning approval for its twice-yearly injectable HIV drug Sunlenca (lenacapavir) as pre-exposure prophylaxis (PrEP) for the prevention of HIV with positive results from a second Phase III registrational trial.
Gilead Hits Mark With Second Long-Acting HIV PrEP Trial
The company stands a strong chance of winning approval for lenacapavir as a twice-yearly injectable drug for preventing HIV infection, though market challenges remain.
